These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 20620441)

  • 1. Toxicities of the thrombopoietic growth factors.
    Cuker A
    Semin Hematol; 2010 Jul; 47(3):289-98. PubMed ID: 20620441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura.
    Wang T; Wang Z; Yang R
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):172-83. PubMed ID: 20378370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia.
    Cuker A; Chiang EY; Cines DB
    Curr Drug Saf; 2010 Apr; 5(2):171-81. PubMed ID: 19534637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
    Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
    J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
    Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA; Pullarkat V
    Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic immune thrombocytopenic purpura. New agents.
    Rodeghiero F; Ruggeri M
    Hamostaseologie; 2009 Jan; 29(1):76-9. PubMed ID: 19151853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietic agents: there is still much to learn.
    Bussel JB; Lakkaraja M
    Presse Med; 2014 Apr; 43(4 Pt 2):e69-78. PubMed ID: 24680422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.